

US Family Health Plan

Prior Authorization Request Form for testosterone undecanoate capsules (**Jatenzo, Kyzatrex, Tlando**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

**Step
1**

Medication requested:

**Step
2**

Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID # _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

**Step
3**

Please complete the clinical assessment:

1. Is the requested medication being used for female-to-male gender reassignment (endocrinologic masculinization)?	<input type="checkbox"/> Yes SKIP to question 7	<input type="checkbox"/> No Proceed to question 2
2. Is the patient a male who is greater than 17 years of age?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No STOP Coverage not approved
3. Does the patient have a diagnosis of hypogonadism as evidenced by 2 or more morning total testosterone levels below 300 ng/dL?	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No STOP Coverage not approved
4. Has the provider investigated the etiology of the low testosterone levels and acknowledges that testosterone therapy is clinically appropriate and needed?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No STOP Coverage not approved
5. Is the patient experiencing symptoms usually associated with hypogonadism?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No STOP Coverage not approved
6. Has the patient tried Fortesta (testosterone 2% gel) or testosterone 1% gel (Androgel 1% generic) for a minimum of 90 days AND failed to achieve total serum testosterone levels above 400 ng/dL (labs drawn 2 hours after Fortesta or testosterone 1% gel (Androgel 1% generic) application) AND without improvement in symptoms?	<input type="checkbox"/> Yes SKIP to question 15	<input type="checkbox"/> No SKIP to question 13

USFHP Prior Authorization Request Form for
testosterone undecanoate capsules (**Jatenzo, Kyzatrex, Tlando**)

7. Does the patient have a diagnosis of gender dysphoria made by a USFHP-authorized mental health provider according to most current edition of the DSM?	<input type="checkbox"/> Yes Proceed to question 8	<input type="checkbox"/> No STOP Coverage not approved
8. Is the patient 16 years of age or older?	<input type="checkbox"/> Yes Proceed to question 9	<input type="checkbox"/> No STOP Coverage not approved
9. Is the patient a biological female of childbearing potential?	<input type="checkbox"/> Yes Proceed to question 10	<input type="checkbox"/> No SKIP to question 11
10. Is the patient pregnant or breastfeeding?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 11
11. Has the patient experienced puberty to at least Tanner stage 2?	<input type="checkbox"/> Yes Proceed to question 12	<input type="checkbox"/> No STOP Coverage not approved
12. Does the patient have psychiatric comorbidity that would confound a diagnosis of gender dysphoria or interfere with treatment (for example: unresolved body dysmorphic disorder; schizophrenia or other psychotic disorders that have not been stabilized with treatment)?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 13
13. Does the patient have a contraindication to Fortesta or testosterone 1% gel (Androgel 1% generic) that does not apply to the requested medication?	<input type="checkbox"/> Yes Proceed to question 15	<input type="checkbox"/> No Proceed to question 14
14. Does the patient require a testosterone replacement therapy that has a low risk of skin-to-skin transfer between family members?	<input type="checkbox"/> Yes Proceed to question 15	<input type="checkbox"/> No STOP Coverage not approved
15. Does the patient have carcinoma of the breast or suspected prostate cancer?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 16
16. Does the patient have uncontrolled hypertension or are they at risk for cardiovascular events (for example, myocardial infarction or stroke) prior to starting therapy with the requested medication?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 17
17. Will the requested medication be used concomitantly with another testosterone replacement therapy product?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Sign and date below

Step 4 I certify the above is true to the best of my knowledge. Please sign and date:

Prescriber Signature

Date